Navigation Links
Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial
Date:1/22/2013

SEATTLE, Jan. 22, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced the successful completion of the 90-day safety database lock in the second of the Company's two pivotal Phase 3 clinical trials evaluating OMS302 in patients undergoing intraocular lens replacement surgery. OMS302, added to standard irrigation solution used during ophthalmological procedures, is Omeros' proprietary PharmacoSurgery™ product designed to maintain intraoperative mydriasis and reduce postoperative pain and irritation resulting from cataract and other lens replacement surgery. In November 2012, Omeros announced that OMS302 met the co-primary efficacy endpoints in this second pivotal Phase 3 clinical trial by demonstrating statistically significant (p<0.00001) maintenance of intraoperative mydriasis (pupil dilation) and statistically significant (p=0.0002) reduction of pain in the early postoperative period.

This multicenter, double-blind, Phase 3 clinical trial enrolled 416 patients randomized 1:1 to receive either OMS302 or placebo. Safety data were collected through postoperative day 90. In this Phase 3 clinical trial, OMS302 was well tolerated. The incidence of adverse events was similar between the two treatment groups, and the adverse event profile was similar to that seen in prior OMS302 clinical trials. No safety concerns have been identified in the OMS302 clinical development program. Results from this study are expected to be presented at an upcoming major ophthalmology meeting. Omeros also plans to publish the results in a leading peer-reviewed ophthalmology journal.

"While these data were expected, they underscore the safety benefits of intraoperative and local delivery of OMS302 – administration of efficacious and low concentrations of the active ingredients directly to the surgical site reduces systemic uptake an
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
2. Omeros to Present at the 24th Annual Piper Jaffray Health Care Conference
3. Omeros is Not Aware of Any Justification for Share Price Movement
4. Omeros Corporation Reports Third Quarter 2012 Financial Results
5. Omeros Responds to Misleading Announcement by Davis Wright Tremaine Concerning Settlement with Former Chief Financial Officer
6. Omeros Ophthalmology Product OMS302 Successful in Second Phase 3 Clinical Trial
7. Omeros Files Investigational New Drug Application for Lead Compound in PDE10 Program
8. Omeros to Present at Two Upcoming Conferences
9. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
10. Omeros Corporation Reports Second Quarter 2012 Financial Results
11. Omeros Announces Discovery in MASP-2 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015 With increasing clinical ... experiencing a rise in active partnerships. The primary ... nations to quantitate CD4 cell markers in human ... http://photos.prnewswire.com/prnh/20150831/262206LOGO New analysis ... Flow Cytometry Market ( http://www.frost.com/nf0e ), finds the ...
(Date:8/31/2015)... Pa. , Aug. 31, 2015  The departments ... an event today at Gaudenzia Concept 90 to raise ... drug overdose crisis in Pennsylvania ... treatment and focus on recovery through the Building ... many Pennsylvanians are dying every day to a disease ...
(Date:8/31/2015)...  Diplomat Pharmacy, Inc. (NYSE: DPLO ), the nation,s ... , Chairman & CEO, and Sean Whelan , CFO, ... Mr. Hagerman and Mr. Whelan are scheduled to participate in ... on Wednesday, September 9, 2015 at 1:45 PM ... scheduled to participate in the Robert W. Baird 2015 Healthcare ...
Breaking Medicine Technology:Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 2Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 3Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 4Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2Diplomat to Participate in Upcoming Investor Conferences 2
... Blumenthal,Cancer Center at Carolinas Medical Center (CMC) in ... a study that could lead to individualized,treatments for ... hospital system,outside Moffitt,s home state of Florida to ... will enroll more than 2,300 patients in,the study, ...
... of patients remain symptom-free and off daily GERD ... after transoral incisionless ... EndoGastric Solutions, the,world leader in natural orifice surgery ... of 1-year follow-up on GERD patients,in the phase ...
Cached Medicine Technology:CMC, Moffitt Partner to Study Cancer 2EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study 2EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study 3EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study 4
(Date:8/31/2015)... ... August 31, 2015 , ... In preparation for this November’s National Family ... BEAN™ personal sound amplifier, is offering caregivers “7 Reasons to Care about Hearing Health.” ... coping with a variety of home healthcare challenges, specifically as they relate to caring ...
(Date:8/31/2015)... VA (PRWEB) , ... August 31, 2015 , ... For ... its supporters have acknowledged September 26th as Mesothelioma Awareness Day . On this ... interested allies with several ways of becoming involved and helping the cause. , “One ...
(Date:8/31/2015)... ... August 31, 2015 , ... MeYou Health ®, a ... mobile walking app, Walkadoo , by including an in-app step tracker. , ... to each person’s walking habits. Rather than broadly assign every Walkadoo member 10,000 steps ...
(Date:8/31/2015)... ... August 31, 2015 , ... It’s a lot like coming home. Life-long ... of Geneva. During his first days on the job, he’s run into residents of ... and I like knowing that they’re living in such a wonderful place,” he said. ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... Exchange and Organization Supporting Business Owners and provided a tour of their North ... represents the success possible to international companies expanding business in the U.S. ...
Breaking Medicine News(10 mins):Health News:Etymotic Offers Caregivers “7 Reasons to Care about Hearing Health” 2Health News:Etymotic Offers Caregivers “7 Reasons to Care about Hearing Health” 3Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 2Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 3Health News:Walkadoo™ Walking Program Now Includes In-app Step Tracker 2Health News:Friendship Senior Options Welcomes New Executive Director for GreenFields of Geneva 2Health News:PartnerTech Supports Economic Growth as Host 2
... What else could you do with,$150,000? That,s the ... and makeup for Gov. Sarah Palin., Contrast ... outfitted in scrubs,for just $10 for a hospital ... scrubs," notes Geri Jenkins, RN, co-president of the ...
... to present at the 2008 Life Sciences and Healthcare Venture Summit October 30, ... ... 2008 -- Curemark announced today that it has been chosen to ... to be held in New York City., , ,The 2008 Life Sciences and ...
... population and increasing concerns for oral hygiene are considered the main factors ... is projected to reach $12.7 billion by the year 2012. , ... ... is one of the most dynamic segments of the oral care market. ...
... 29 The Ensign,Group, Inc. (Nasdaq: ENSG ... of,skilled nursing, rehabilitative care services and assisted living,companies, ... nursing,facilities in Texas and California for an aggregate ... ), Previously leased facilities now owned, ...
... 28 Today the ... responded to a request ... to hold an unnecessary,debate., ... letters, please visit:, http://www.noonprop8.com/downloads/FSchubert102808.pdf ...
... ATSI ), manufacturer and marketer of state-of-the-art ... will release,financial results for the third quarter ended ... November 3, 2008. The Company will host a,conference ... at 5:00 p.m.,Eastern Time (2:00 p.m. Pacific Time) ...
Cached Medicine News:Health News:Nurses Present Palin Clothing Line Website ... and Other Ways the Money Could Have Been Spent 2Health News:Curemark to Present at the 2008 Life Sciences & Healthcare Venture Summit 2008 2Health News:Global Toothpaste Market to Reach $12.7 Billion by 2012, According to a New Report by Global Industry Analysts, Inc. 2Health News:Global Toothpaste Market to Reach $12.7 Billion by 2012, According to a New Report by Global Industry Analysts, Inc. 3Health News:The Ensign Group, Inc. Acquires Four Skilled Nursing Facilities 2Health News:ATS Medical Announces Third Quarter 2008 Earnings Release Date and Conference Call 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: